Literature DB >> 35916511

Chemistries of bifunctional PROTAC degraders.

Chaoguo Cao1,2, Ming He1, Liguo Wang1, Yuna He1, Yu Rao1.   

Abstract

Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has received extensive attention from both academia and industry as it can potentially access previously inaccessible targets. However, the design and optimization of PROTACs present big challenges for researchers, and the general strategy for its development and optimization is a lot of trial and error based on experience. This review highlights the important advances in this rapidly growing field and critical limitations of the traditional trial-and-error approach to developing PROTACs by analyzing numerous representative examples of PROTACs development. We summarize and analyze the general principles and strategies for PROTACs design and optimization from the perspective of chemical structure design, and propose potential future pathways to facilitate the development of PROTACs.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35916511     DOI: 10.1039/d2cs00220e

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   60.615


  2 in total

Review 1.  Small-Molecule PROTACs for Cancer Immunotherapy.

Authors:  Zefan Liu; Yajun Zhang; Yucheng Xiang; Xin Kang
Journal:  Molecules       Date:  2022-08-25       Impact factor: 4.927

Review 2.  MDM2-Based Proteolysis-Targeting Chimeras (PROTACs): An Innovative Drug Strategy for Cancer Treatment.

Authors:  André T S Vicente; Jorge A R Salvador
Journal:  Int J Mol Sci       Date:  2022-09-21       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.